Participated · Seed · May 2026

ParcelBio develops an APEXm (Amplified and Prolonged EXpression mRNA) platform that uses novel RNA domains to enhance protein expression and extend activity for mRNA medicines. Its lead program is an in vivo CAR-T therapy targeting pathogenic B cells aimed at achieving deep B-cell depletion for durable, drug-free remission in autoimmune disease. The company is also advancing programs in oncology and encoded protein therapeutics. ParcelBio emphasizes enabling sustained CAR expression without viral delivery or ex vivo manufacturing to create scalable, off-the-shelf therapies. The company is led by cofounders David Weinberg (CEO) and Chris Carlson (CSO) and is based in San Francisco. ParcelBio announced a $13M Seed round to fund further development of its platform and pipeline.

Participated · Equity · Mar 2025

Olio Labs operates an AI-powered therapeutic design platform centered on a combination design engine (CoDE) that integrates human medical records and biological data, in‑vivo phenomic screening, and neural and endocrine circuit maps. The platform fuses computational methods with biological expertise to shift pharmaceutical research from a molecule-first to a patient-first approach. Olio Labs highlights AI-powered integration of biological expertise as a core capability of CoDE. Led by CEO David Tingley, the company plans to use the new capital to expand operations and advance its development efforts. Its advisory board includes industry veterans Patricia Martin, Michael Schwartz, and Hugh Reinhoff. The company announced the funding in March 2025. Olio Labs uses artificial intelligence and machine learning to design combination therapeutics that account for complex interactions among thousands of proteins. Their AI-driven compute-experiment platform can design and test trillions of combinations, which the company says has accelerated discovery fourfold and reduced costs by 90%. Olio Labs is focused on discovering combinations that can outperform best-in-class obesity drugs and has reported promising results in animal models, including significant appetite reduction with associated decreases in nausea. The platform targets both combinations of existing drugs and novel targets. The company was founded by Dr. David Tingley and Dr. Tom Roseberry, whose backgrounds include Harvard, New York University, and Neuralink, and the team is expanding to accelerate research. Olio Labs participated in Y Combinator’s S23 batch and recently attracted investment from ZAKA VC.

Participated · Equity · Nov 2024

Founded in 2018, Webel operates a digital marketplace for home services and currently serves more than 2 million users with around 350,000 registered professionals and nearly one million service listings. The platform operates in 31 Spanish cities and has recently started expanding into the United Kingdom. Webel offers more than 30 service categories, including cleaning, ironing, handyman work, small renovations, moving services, tutoring, childcare and appliance repair. The company emphasizes a cost structure that delivers prices typically 30–40% lower than competitors while charging professionals lower-than-average commissions and allowing them control over pricing, schedules and clients. Webel’s immediate plans include strengthening its presence in Spain and growing visibility for newer service categories. The recently raised €4.3M pre-Series A round will be used mainly for marketing and product development to support those plans.

Led · Seed · Oct 2024

ExoMatter provides an AI-driven materials R&D platform that ingests material data from scientific sources and processes it to deliver physical, chemical and engineering properties, sustainability metrics, and cost indicators. The platform leverages AI and quantum chemical modeling to help researchers and developers evaluate and select materials for industrial, chemical and manufacturing applications. ExoMatter says its tools are designed to cut materials costs and reduce carbon emissions. The company already works with several DAX-listed customers, including Airbus and Infineon, which the founders cite as early proof points. Founders Dr. Josua Vieten (CEO) and Barbara Bachus (COO) bring backgrounds in chemistry/materials science and R&D coordination, respectively. ExoMatter closed a €1.7M pre-seed round and plans to further automate and scale the platform while pursuing a follow-on funding round next year.

Participated · Seed · Sep 2023

Deskree is a Canadian‑Ukrainian no-code tool that provides back-end infrastructure for developers. The company is led by founder Dmytro Grechko. Articles report strong user growth, though no specific metrics were provided. Deskree recently raised $1.5 million to support further user growth and product development. The announcement was shared on LinkedIn and linked to an exclusive interview by Silicon Canals. The team is described as strong and growth‑oriented. No revenue or other financial metrics were disclosed in the article.